Information Technology
Equasens: 2023 Annual Results
Villers-lès-Nancy, 29 March 2024 - 6:00 p.m. (CET)
PRESS RELEASE
2023 Annual Results
On 29 March 2024, the Board of Directors of EQUASENS, chaired by Thierry CHAPUSOT, examined and approved the financial statements for the year ended 31 December 2023 in the presence of the Statutory Auditors. The audit procedures for the consolidated accounts have been completed. The auditors' report will be issued after the management report has been reviewed and the procedures for filing the finalised annual report have been completed.
_____
As a reminder, acquisitions completed by Equasens Group in 2023:
The following changes in the scope of consolidation took place on 1 January 2023:
Equasens Group reported annual revenue of €219.7m, up 2.6% on 2022, despite an unfavourable comparison base linked to the boost provided by the Ségur digital healthcare investment programme and a difficult economic climate, particularly in the pharmacy market.
This trend can be explained by several factors:
Conversely:
Despite a modest decline in Current Operating Profit by 1.7% to €55.8m at 31 December 2023 , the Group's profitability remains at a high level, with a current operating margin of 25.4%. Significant efforts in terms of recruitment were made during the period to strengthen the sales and development teams of all the Divisions. The resulting impact on payroll, including inflation-linked increases, was €5m.
Net Profit rose to €48.9m (+0.4%) and Net Profit Attributable to Equity Holders of the Parent to €47.0m (+1.4%). At 31 December 2023, Basic Earnings per Share amounted to €3.13 , up from €3.09 one year earlier (+1.4%).
Equasens Group, maintaining its dividend policy, will submit a proposal to the Annual General Meeting on 27 June 2024 for payment of a gross dividend of €1.25 per share (+9.2%).
Shareholders' equity stood at €227.6m at 31 December 2023 compared to €196.8m at the end of 2022.
Cash flow after interest and tax remained stable at €61.6m.
Significant capital expenditures were made in 2023 linked to a new network infrastructure which is expected to provide the Group with significant capacity for hosting healthcare data.
With a gross cash position of €137.0m and a net financial surplus of €67.7m, up 24.4%, the Group has a high degree of autonomy and capacity for investment.
On the proposal of Denis SUPPLISSON, Chief Executive Officer, on 29 March 2024 the Board of Directors approved the appointment of Mr Damien VALICON, currently Head of the PHARMAGEST Division, as non-administrator Deputy Chief Executive Officer.
Damien VALICON , 53, LinkedIn - Multi-entrepreneur, has also held various sales management positions as a distributor of medical equipment and solutions, notably for Trophy Radiologie. Since 2001, he has held senior management positions with healthcare solution providers and software companies. In 2011, he became Chief Business Development Officer of AxiSanté, a subsidiary of the German group, CompuGroup Medical. In 2014, he was appointed Chief Executive Officer of Julie Solutions, a subsidiary of the US-based Henry Schein Group before returning to Compugroup Medical Solutions as Chief Executive Officer.
Damien VALICON joined Equasens Group on 10 January 2022 as Manager of the French Pharmacy Business Unit. On 2 January 2023, he was appointed Head of the Medical Solutions Division. Since January 2024, he has headed the PHARMAGEST Division, which covers all solutions for pharmacies in France and Europe.
Damien VALICON will join Denis SUPPLISSION, Chief Executive Officer, and Grégoire de ROTALIER, Deputy Chief Executive Officer, as a member of the Executive Board.
Financial calendar:
About Equasens Group
With more than 1,400 employees, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.
With operations in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.
Listed on Euronext Paris™ - Compartment B
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC SMALL and CAC All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS
Get all the news about the Equasens Group www.equasens.com and on LinkedIn
CONTACTS
Analyst and Investor Relations:
Chief Administrative and Financial Officer : Frédérique Schmidt
Tel. +33 (0) 83 15 90 67 - frederique.schmidt@equasens.com
Media Relations:
FIN'EXTENSO - Isabelle Aprile
Tel. +33 (0)3 17 38 61 78 - i.aprile@finextenso.fr
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti